Acuta Capital Partners as of Dec. 31, 2020
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 51 positions in its portfolio as reported in the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Celldex Therapeutics Com New (CLDX) | 7.8 | $29M | 1.6M | 17.52 | |
| Sage Therapeutics (SAGE) | 6.0 | $22M | 256k | 86.51 | |
| Kura Oncology (KURA) | 5.7 | $21M | 638k | 32.66 | |
| Larimar Therapeutics (LRMR) | 5.0 | $19M | 863k | 21.41 | |
| Mersana Therapeutics (MRSN) | 5.0 | $19M | 694k | 26.61 | |
| Compass Pathways Sponsored Ads (CMPS) | 4.1 | $15M | 319k | 47.64 | |
| Vistagen Therapeutics Com New | 4.0 | $15M | 7.5M | 1.94 | |
| Athira Pharma (ATHA) | 3.7 | $14M | 393k | 34.25 | |
| Immunovant (IMVT) | 3.6 | $13M | 284k | 46.19 | |
| Trillium Therapeutics Com New | 3.2 | $12M | 803k | 14.71 | |
| Arrowhead Pharmaceuticals (ARWR) | 2.9 | $11M | 139k | 76.73 | |
| 89bio (ETNB) | 2.9 | $11M | 434k | 24.37 | |
| Syndax Pharmaceuticals (SNDX) | 2.8 | $10M | 466k | 22.24 | |
| Apellis Pharmaceuticals (APLS) | 2.6 | $9.6M | 167k | 57.20 | |
| Bcls Acquisition Corp Com Cl A | 2.6 | $9.4M | 843k | 11.14 | |
| Surface Oncology | 2.5 | $9.2M | 1000k | 9.24 | |
| Catalyst Biosciences Com New | 2.3 | $8.6M | 1.4M | 6.31 | |
| Iveric Bio | 2.3 | $8.4M | 1.2M | 6.91 | |
| Fulcrum Therapeutics (FULC) | 2.2 | $8.0M | 683k | 11.71 | |
| Replimune Group (REPL) | 2.2 | $7.9M | 208k | 38.15 | |
| Iovance Biotherapeutics (IOVA) | 2.1 | $7.6M | 165k | 46.40 | |
| Concert Pharmaceuticals I equity | 1.8 | $6.8M | 538k | 12.64 | |
| Altimmune Com New (ALT) | 1.8 | $6.5M | 579k | 11.28 | |
| Avidity Biosciences Ord (RNA) | 1.7 | $6.3M | 246k | 25.52 | |
| Jiya Acquisition Corp Com Cl A | 1.6 | $5.8M | 563k | 10.30 | |
| Stoke Therapeutics (STOK) | 1.6 | $5.7M | 93k | 61.94 | |
| Verastem | 1.4 | $5.1M | 2.4M | 2.13 | |
| Health Sciences Acq Corp 2 Ord Shs | 1.4 | $5.0M | 393k | 12.81 | |
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 1.3 | $4.7M | 705k | 6.68 | |
| Curis Com New | 1.2 | $4.3M | 530k | 8.19 | |
| Biohaven Pharmaceutical Holding Call Option | 1.2 | $4.3M | 50k | 85.72 | |
| Praxis Precision Medicines I | 1.1 | $4.2M | 76k | 55.02 | |
| Rapt Therapeutics (RAPT) | 1.1 | $4.1M | 210k | 19.75 | |
| Relmada Therapeutics (RLMD) | 1.0 | $3.8M | 120k | 32.07 | |
| C4 Therapeutics Com Stk (CCCC) | 1.0 | $3.6M | 110k | 33.13 | |
| Madrigal Pharmaceuticals (MDGL) | 1.0 | $3.6M | 33k | 111.17 | |
| Clearside Biomedical (CLSD) | 0.9 | $3.4M | 1.3M | 2.74 | |
| Cymabay Therapeutics | 0.5 | $1.9M | 330k | 5.74 | |
| Oncorus | 0.5 | $1.7M | 54k | 32.34 | |
| Aldeyra Therapeutics (ALDX) | 0.4 | $1.3M | 193k | 6.86 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $1.2M | 80k | 15.38 | |
| Cyclacel Pharmaceuticals | 0.3 | $1.2M | 150k | 7.81 | |
| Rocket Pharmaceuticals (RCKT) | 0.3 | $1.1M | 20k | 54.85 | |
| Pmv Pharmaceuticals (PMVP) | 0.3 | $923k | 15k | 61.53 | |
| Wave Life Sciences SHS (WVE) | 0.2 | $846k | 108k | 7.87 | |
| 4d Molecular Therapeutics In (FDMT) | 0.2 | $829k | 20k | 41.45 | |
| Annexon (ANNX) | 0.2 | $626k | 25k | 25.04 | |
| Karuna Therapeutics Ord | 0.1 | $508k | 5.0k | 101.60 | |
| Axsome Therapeutics (AXSM) | 0.1 | $489k | 6.0k | 81.50 | |
| Panacea Acquisition Corp *w Exp 07/07/202 | 0.1 | $299k | 93k | 3.20 | |
| Novavax Com New (NVAX) | 0.1 | $279k | 2.5k | 111.60 |
